Serplulimab with chemotherapy before surgery for limited-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests adding an immunotherapy drug called serplulimab to standard chemotherapy before surgery for limited-stage small cell lung cancer (LS-SCLC). The goal is to see if this combination helps shrink the tumor and improve outcomes for patients who have not received prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old
- You must have a confirmed diagnosis of small cell lung cancer that is limited-stage (stage IIB to IIIB with N2 involvement)
- You must not have received any prior cancer treatment like chemotherapy, immunotherapy, or chest radiation
- You must be healthy enough to have surgery, with good organ function (e.g., liver, kidneys, bone marrow)
- You must not have active infections like HIV, hepatitis B or C, or tuberculosis, or uncontrolled autoimmune disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, lurbinectedin and serplulimab, as maintenance therapy after initial chemotherapy for people with extensive-stage small cell lung cancer (SCLC) that hasn't spread to the brain. The goal is to see if this approach helps keep the cancer from growing for longer.
This trial tests a combination of low-dose radiation to the chest, immunotherapy (adebrelimab), and chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this approach can help control the cancer better than standard treatments and potentially improve outcomes.
This trial tests a new combination of two drugs (YL201 and serplulimab) for people with extensive-stage small cell lung cancer who have not yet received treatment. The goal is to see if the combination helps shrink or control the cancer.
This study is testing a new combination treatment for early-stage small-cell lung cancer. It compares giving immunotherapy drugs (PD-1/PD-L1 inhibitors) along with chemotherapy before surgery versus chemotherapy alone, to see if the combination helps shrink tumors more effectively and improves outcomes.
This trial is testing whether adding the immunotherapy drug serplulimab to standard chemotherapy and radiation can help people with limited-stage small cell lung cancer. It is for those who have not had any previous treatment for their cancer.
This trial tests whether giving a combination of an immunotherapy drug (adebrelimab) and chemotherapy before surgery, followed by surgery and radiation, is effective for limited-stage small cell lung cancer. The goal is to see if this approach helps control the cancer better than standard treatment alone.
Hear when a new SCLC, Limited Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.